Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367160 | 0.92 | STS (0.48) | SMN1; SMN2NPC1RAB9AHTTKMT2A | |
| SCHEMBL20400129 | 0.88 | HTT (0.48) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL26627091 | 0.84 | PDE4B (0.46) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL6947042 | 0.83 | PDE4B (0.44) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL951538 | 0.83 | KMT2A (0.59) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL21551011 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL24041196 | 0.82 | STS (0.46) | SMN1; SMN2NPC1RAB9AHTTKMT2A | |
| SCHEMBL28546986 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL28550674 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL26077281 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626032-B2 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080214608-A1 | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2008-09-04 | — | — | US | disclosed |
| US-7393957-B2 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED (IN) | 2008-07-01 | — | — | US | disclosed |
| US-6964966-B2 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED (IN) | 2005-11-15 | — | — | US | disclosed |
| US-6878713-B2 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED (IN) | 2005-04-12 | — | — | US | disclosed |
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2005-03-24 | — | — | US | disclosed |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | WOCKHARDT LIMITED | 2003-11-20 | — | — | US | disclosed |
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | SMN1; SMN2 4719/4885NPC1 1865/4885RAB9A 508/4885 |
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | SMN1; SMN2 4719/4885NPC1 1865/4885RAB9A 508/4885 |
| US-20080214608-A1 | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | SMN1; SMN2 4727/4885NPC1 2108/4885RAB9A 659/4885 |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | SMN1; SMN2 4719/4885NPC1 1865/4885RAB9A 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.